{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:18:11Z","timestamp":1783703891195,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40263-026-01305-9","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:57:18Z","timestamp":1781528238000},"page":"1089-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential:\u00a0A Systematic Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-6076","authenticated-orcid":false,"given":"Edward","family":"Willow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Chaudhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajbala","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9464-5488","authenticated-orcid":false,"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"1305_CR1","unstructured":"US Food and Drug Administration. Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for OTC Human Use (Final Administrative Order OTC000026). 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/omuf\/monographs\/OTC%20Monograph_M012-Cough%20Cold%20Allergy%20Bronchodilator%20and%20Antiasthmatic%20Drug%20Products%20for%20OTC%20Human%20Use%2010.14.2022.pdf."},{"issue":"1","key":"1305_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1196\/annals.1432.003","volume":"1139","author":"JA Banken","year":"2008","unstructured":"Banken JA, Foster H. Dextromethorphan: an emerging drug of abuse. Ann N Y Acad Sci. 2008;1139(1):402\u201311. https:\/\/doi.org\/10.1196\/annals.1432.003.","journal-title":"Ann N Y Acad Sci"},{"issue":"7\u20138","key":"1305_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/dta.1620","volume":"6","author":"H Morris","year":"2014","unstructured":"Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal. 2014;6(7\u20138):614\u201332. https:\/\/doi.org\/10.1002\/dta.1620.","journal-title":"Drug Test Anal"},{"issue":"5","key":"1305_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/15563650.2011.585429","volume":"49","author":"MD Wilson","year":"2011","unstructured":"Wilson MD, Ferguson RW, Mazer ME, Litovitz TL. Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000\u20132010. Clin Toxicol. 2011;49(5):409\u201315. https:\/\/doi.org\/10.3109\/15563650.2011.585429.","journal-title":"Clin Toxicol"},{"issue":"7","key":"1305_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1080\/15563650.2017.1416124","volume":"56","author":"S Karami","year":"2018","unstructured":"Karami S, Major JM, Calderon S, McAninch JK. Trends in dextromethorphan cough and cold products: 2000\u20132015 National Poison Data System intentional abuse exposure calls. Clin Toxicol. 2018;56(7):656\u201363. https:\/\/doi.org\/10.1080\/15563650.2017.1416124.","journal-title":"Clin Toxicol"},{"issue":"7","key":"1305_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/000992280504400702","volume":"44","author":"RH Schwartz","year":"2005","unstructured":"Schwartz RH. Adolescent abuse of dextromethorphan. Clin Pediatr. 2005;44(7):565\u20138. https:\/\/doi.org\/10.1177\/000992280504400702.","journal-title":"Clin Pediatr"},{"issue":"10","key":"1305_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40263-023-01032-5.","volume":"37","author":"D Akbar","year":"2023","unstructured":"Akbar D, Rhee TG, Ceban F, Ho R, Teopiz KM, Cao B, et al. Dextromethorphan-bupropion for the treatment of depression: a systematic review of efficacy and safety in clinical trials. CNS Drugs. 2023;37(10):867\u201381. https:\/\/doi.org\/10.1007\/s40263-023-01032-5.","journal-title":"CNS Drugs"},{"issue":"3","key":"1305_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/ALN.0000000000000950","volume":"124","author":"MR King","year":"2016","unstructured":"King MR, Ladha KS, Gelineau AM, Anderson TA. Perioperative dextromethorphan as an adjunct for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2016;124(3):696. https:\/\/doi.org\/10.1097\/ALN.0000000000000950.","journal-title":"Anesthesiology"},{"issue":"1","key":"1305_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11586000-000000000-00000","volume":"25","author":"PH Gordon","year":"2011","unstructured":"Gordon PH. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs. 2011;25(1):1\u201315. https:\/\/doi.org\/10.2165\/11586000-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"7","key":"1305_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2165\/00023210-200822070-00001","volume":"22","author":"HS Wortzel","year":"2008","unstructured":"Wortzel HS, Oster TJ, Anderson CA, Arciniegas DB. Pathological laughing and crying: epidemiology, pathophysiology and treatment. CNS Drugs. 2008;22(7):531\u201345. https:\/\/doi.org\/10.2165\/00023210-200822070-00001.","journal-title":"CNS Drugs"},{"issue":"5","key":"1305_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/11207260-000000000-00000","volume":"25","author":"KP Garnock-Jones","year":"2011","unstructured":"Garnock-Jones KP. Dextromethorphan\/quinidine: in pseudobulbar affect. CNS Drugs. 2011;25(5):435\u201345. https:\/\/doi.org\/10.2165\/11207260-000000000-00000.","journal-title":"CNS Drugs"},{"key":"1305_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103454","author":"S Roesner","year":"2025","unstructured":"Roesner S, Donar A, Donahue NL, Shekoski D, Kernen S, Walstrom J, et al. Evaluation of compounds with Sigma-1 Receptor agonism in behavioral models for anti-compulsive and antidepressant drug effects in mice (Abstract ID: 191169). J Pharmacol Exp Ther. 2025. https:\/\/doi.org\/10.1016\/j.jpet.2025.103454.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1305_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089985","volume":"9","author":"L Nguyen","year":"2014","unstructured":"Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS\u00a0One. 2014;9(2):e89985. https:\/\/doi.org\/10.1371\/journal.pone.0089985.","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"1305_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1017\/S1092852919001470","volume":"24","author":"SM Stahl","year":"2019","unstructured":"Stahl SM. Dextromethorphan\/bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr. 2019;24(5):461\u20136. https:\/\/doi.org\/10.1017\/S1092852919001470.","journal-title":"CNS Spectr"},{"key":"1305_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","volume":"164","author":"CP Taylor","year":"2016","unstructured":"Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use. Pharmacol Ther. 2016;164:170\u201382. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.04.010.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1305_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s002130051087","volume":"146","author":"KL Nicholson","year":"1999","unstructured":"Nicholson KL, Hayes BA, Balster RL. Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology. 1999;146(1):49\u201359. https:\/\/doi.org\/10.1007\/s002130051087.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1305_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0022-3565(25)32735-7","volume":"218","author":"AM Young","year":"1981","unstructured":"Young AM, Woods JH. Maintenance of behavior by ketamine and related compounds in rhesus monkeys with different self-administration histories. J Pharmacol Exp Ther. 1981;218(3):720\u20137. https:\/\/doi.org\/10.1016\/S0022-3565(25)32735-7.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1305_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF02245325","volume":"116","author":"SG Holtzman","year":"1994","unstructured":"Holtzman SG. Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology. 1994;116(3):249\u201354. https:\/\/doi.org\/10.1007\/BF02245325.","journal-title":"Psychopharmacology"},{"key":"1305_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2016_462","volume":"36","author":"KH Preller","year":"2018","unstructured":"Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci. 2018;36:221\u201356. https:\/\/doi.org\/10.1007\/7854_2016_462.","journal-title":"Curr Top Behav Neurosci"},{"key":"1305_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106086","author":"B Romeo","year":"2025","unstructured":"Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Aurore B, et al. The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2025. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106086.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1305_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-012-2680-6","volume":"223","author":"CJ Reissig","year":"2012","unstructured":"Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology. 2012;223(1):1\u201315. https:\/\/doi.org\/10.1007\/s00213-012-2680-6.","journal-title":"Psychopharmacology"},{"issue":"10","key":"1305_CR22","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s00213-018-4981-x","volume":"235","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology. 2018;235(10):2915\u201327. https:\/\/doi.org\/10.1007\/s00213-018-4981-x.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1305_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","volume":"235","author":"TM Carbonaro","year":"2018","unstructured":"Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology. 2018;235(2):521\u201334. https:\/\/doi.org\/10.1007\/s00213-017-4769-4.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1305_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/0304-3940(91)90101-X","volume":"124","author":"J Church","year":"1991","unstructured":"Church J, Shacklock JA, Baimbridge KG. Dextromethorphan and phencyclidine receptor ligands: differential effects on K+-and NMDA-evoked increases in cytosolic free Ca2+ concentration. Neurosci Lett. 1991;124(2):232\u20134. https:\/\/doi.org\/10.1016\/0304-3940(91)90101-X.","journal-title":"Neurosci Lett"},{"issue":"4","key":"1305_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/ANA.0b013e31817f523f","volume":"20","author":"IR Kamel","year":"2008","unstructured":"Kamel IR, Wendling WW, Chen D, Wendling KS, Harakal C, Carlsson C. N-Methyl-D-aspartate (NMDA) antagonists\u2014S (+)-ketamine, dextrorphan, and dextromethorphan\u2014act as calcium antagonists on bovine cerebral arteries. J Neurosurg Anesthesiol. 2008;20(4):241\u20138. https:\/\/doi.org\/10.1097\/ANA.0b013e31817f523f.","journal-title":"J Neurosurg Anesthesiol"},{"key":"1305_CR26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.102","author":"KT Greenway","year":"2025","unstructured":"Greenway KT, Garel N, Dinh-Williams L-AL, L\u00e9vesque JT, Kaelen M, Dagenais-Beaul\u00e9 V, et al. The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression. Br J Psychiatry. 2025. https:\/\/doi.org\/10.1192\/bjp.2025.102.","journal-title":"Br J Psychiatry"},{"key":"1305_CR27","unstructured":"US Food Drug Administration. SPRAVATO (esketamine) nasal spray, prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211243s016lbl.pdf."},{"key":"1305_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1209419","volume":"15","author":"P Wolfson","year":"2024","unstructured":"Wolfson P, Vaid G. Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective\u2014a new and evolving approach. Front Psychiatry. 2024;15:1209419. https:\/\/doi.org\/10.3389\/fpsyt.2024.1209419.","journal-title":"Front Psychiatry"},{"key":"1305_CR29","unstructured":"Pathways C. COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression. 2018. https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2018\/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression\/default.aspx. Accessed 23 Oct 2018."},{"key":"1305_CR30","unstructured":"Usona I. FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder. 2019. https:\/\/www.usonainstitute.org\/updates\/fda-grants-breakthrough-therapy-designation-to-usona-institutes-psilocybin-program-for-major-depressive-disorder. Accessed 22 Nov 2019."},{"key":"1305_CR31","unstructured":"MindMed. MindMed receives FDA Breakthrough Therapy Designation and announces positive 12-week durability data from Phase 2b study of MM120 for generalized anxiety disorder. 2024. https:\/\/ir.definiumtx.com\/news-events\/press-releases\/detail\/137\/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder. Accessed 07 Mar 2024."},{"key":"1305_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1305_CR33","unstructured":"Covidence systematic review software. Veritas Health Innovation. https:\/\/support.covidence.org\/help\/how-can-i-cite-covidence"},{"key":"1305_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"8","key":"1305_CR35","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00213-020-05533-9","volume":"237","author":"TM Carbonaro","year":"2020","unstructured":"Carbonaro TM, Johnson MW, Griffiths RR. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology. 2020;237(8):2293\u2013304. https:\/\/doi.org\/10.1007\/s00213-020-05533-9.","journal-title":"Psychopharmacology"},{"issue":"5","key":"1305_CR36","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1212\/WNL.48.5.1212","volume":"48","author":"KA Nelson","year":"1997","unstructured":"Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High\u2010dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48(5):1212\u20138. https:\/\/doi.org\/10.1212\/WNL.48.5.1212.","journal-title":"Neurology"},{"issue":"3","key":"1305_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.drugalcdep.2012.08.025","volume":"128","author":"LP Carter","year":"2013","unstructured":"Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ. Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug Alcohol Depend. 2013;128(3):206\u201313. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.08.025.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1305_CR38","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/1556-4029.12833","volume":"60","author":"PJ Perry","year":"2015","unstructured":"Perry PJ, Fredriksen K, Chew S, Ip EJ, Lopes I, Doroudgar S, et al. The effects of dextromethorphan on driving performance and the standardized field sobriety test. J Forensic Sci. 2015;60(5):1258\u201362. https:\/\/doi.org\/10.1111\/1556-4029.12833.","journal-title":"J Forensic Sci"},{"issue":"4","key":"1305_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/psymed.2023.0035","volume":"1","author":"DS Mathai","year":"2023","unstructured":"Mathai DS, Hilbert S, Sepeda ND, Strickland JC, Griffiths RR, Garcia-Romeu A. Double-blind comparison of the two hallucinogens dextromethorphan and psilocybin: experience-dependent and enduring psychological effects in healthy volunteers. Psychedelic Med. 2023;1(4):241\u201352. https:\/\/doi.org\/10.1089\/psymed.2023.0035.","journal-title":"Psychedelic Med"},{"key":"1305_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","volume":"64","author":"MP Bogenschutz","year":"2016","unstructured":"Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:250\u20138. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.03.002.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1305_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_464","author":"MP Bogenschutz","year":"2016","unstructured":"Bogenschutz MP, Ross S. Therapeutic applications of classic hallucinogens. Behav Neurobiol Psychedelic Drugs. 2016. https:\/\/doi.org\/10.1007\/7854_2016_464.","journal-title":"Behav Neurobiol Psychedelic Drugs"},{"issue":"4","key":"1305_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/2045125314527985","volume":"4","author":"D Baumeister","year":"2014","unstructured":"Baumeister D, Barnes G, Giaroli G, Tracy D. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol. 2014;4(4):156\u201369. https:\/\/doi.org\/10.1177\/2045125314527985.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"5","key":"1305_CR43","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2174\/1570159X12666140619204251","volume":"12","author":"G Serafini","year":"2014","unstructured":"Serafini G, Howland HR, Rovedi F, Girardi P, Amore M. The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol. 2014;12(5):444\u201361. https:\/\/doi.org\/10.2174\/1570159X12666140619204251.","journal-title":"Curr Neuropharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01305-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:02:19Z","timestamp":1783702939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01305-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01305-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robert H. Dworkin, PhD, since January 1, 2023, has received research grants and contracts from the US FDA and the US National Institutes of Health, and compensation for serving on advisory boards or consulting on clinical trial methods from Aditum, Akigai, Allay, AM-Pharma, Beckley, Biogen, Biohaven, Biosplice, Bsense, Cardialen, Centrexion, Chiesi, Clexio,\u00a0Coalition for Aligning Sciences, Collegium, CombiGene, Confo, Contineum, Eccogene, Editas, Eli Lilly, Emmes, Epizon, Ethismos (equity), Eurofarma, Exicure, GlaxoSmithKline, Glenmark, JCARE, JucaBio, Kriya, Latigo, Mainstay, Maxona, Merck, Mind Medicine (also equity), Nocicera, Noema, Orion, Q-State, Regenacy, Rho, Salvia, Sangamo, Scilex, Semnur, SIMR Biotech, SiteOne, Sparian, SPM Therapeutics, SPRIM Health, Tiefenbacher, Validae, Vertanical, Ventus, Vertex, Viscera, and WCG.\u00a0All other authors have no conflicts of interest relevant to the article\u00a0to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This study did not involve human participants, animals, or identifiable personal data, and therefore did not require institutional ethics committee review or approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. No human participants were involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. No human participants were involved in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable. No custom code or software was used in the preparation of this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"EW, AC, LH, and RD contributed to the study conception and design. EW, AC, and LH performed the research and collected the data. EW, AC, MS, and RD analyzed and interpreted the data. EW drafted the initial manuscript, and AC, MS, RT, and RD critically revised the manuscript for important intellectual content. All authors have read and approved the final version, and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}